Revlimid® available in the UK for newly diagnosed myeloma patients

Celgene Limited, the UK subsidiary of Celgene Corporation, has announced that Revlimid is now licensed in the UK for newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplantation. Licensing approval of Revlimid in this setting was based on data from the FIRST trial, MM-020, which showed that progression-free survival…

Details